Table II.
Baseline clinical characteristics and other treatments of patients receiving ulinastatin treatment.
| Routine blood test | Oxygen saturation | Drugs administered | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient no. | WBC, x109/l | L, % | CRP, mg/l | Concentration of oxygen inhalation, % | SaO2, % | Antiviral | Antibiotic | Antifungal | Corticosteroids |
| 1 | 12.6 | 9.3 | 274.09 | 21 | 90 | None | Moxifloxacin | None | None |
| 2 | 3.0 | 21.1 | 116.65 | 41 | 94 | Lopinavir-Ritonavir | Piperacillin tazobactam | None | Methylprednisolone |
| 3 | 4.4 | 20.8 | 7.52 | 21 | 95 | None | Moxifloxacin | None | None |
| 4 | 3.8 | 18.0 | 25.97 | 29 | 96 | None | None | None | None |
| 5 | 4.8 | 6.3 | 45.66 | 41 | 92 | Umifenovir | Moxifloxacin | Methylprednisolone | |
| 6 | 6.8 | 21.6 | 5.5 | 21 | 92 | Ribavirin, umifenovir | Levofloxacin, cefoperazone sulbactam sodium | None | Methylprednisolone |
| 7 | 5.0 | 29.4 | 20.54 | 21 | 89 | Umifenovir | Moxifloxacin, cefoperazone sulbactam sodium | Voriconazole | None |
| 8 | 5.2 | 20.5 | 24.36 | 29 | 92 | Umifenovir | Moxifloxacin | None | Methylprednisolone |
| 9 | 6.1 | 26.2 | 57.71 | 21 | 86 | Oseltamivir | Moxifloxacin | None | None |
| 10 | 11.9 | 7.4 | 9.51 | 21 | 86 | Umifenovir | Moxifloxacin | None | None |
| 11 | 5.6 | 20.7 | 1.92 | 21 | 92 | Umifenovir | None | None | None |
| 12 | 9.0 | 16.7 | 6.95 | 21 | 93 | Umifenovir | Cefoperazone sulbactam sodium | Voriconazole | Methylprednisolone |
WBC, white blood cell; L, lymphocyte; CRP, C-reactive protein; SaO2, oxygen saturation.